Investigating the role of pyrophosphate in arterial calcification for chronic kidney disease patients
Pyrophosphate: a New Biomarker to Predict Arterial Calcification in Chronic Kidney Disease
This study is testing if low levels of a substance called pyrophosphate are linked to the buildup of calcium in the arteries of people with chronic kidney disease to help find better ways to manage heart risks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 242 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes Maritimes) |
| Trial ID | NCT04950439 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the relationship between low levels of pyrophosphate (PPi) and the development of arterial calcifications in patients with chronic kidney disease (CKD) stages 3 and 4. A total of 252 participants with an estimated glomerular filtration rate (eGFR) between 20 and 59 ml/min/1.73 m² will be recruited and monitored over a three-year period. The study will involve collecting blood samples to assess PPi levels and their correlation with arterial calcification. The findings could provide insights into potential therapeutic strategies for managing cardiovascular risks in CKD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with chronic kidney disease stages 3 or 4 and an eGFR between 20 and 59 ml/min/1.73 m².
Not a fit: Patients who have undergone kidney transplantation or have acute inflammatory diseases or active cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatments that reduce arterial calcification and improve cardiovascular health in patients with chronic kidney disease.
How similar studies have performed: While the specific approach of using pyrophosphate in this context may be novel, previous studies have indicated a link between low PPi levels and arterial calcification in similar patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * eGFR between 59 et 20 ml/min/1,73 m2 twice at three month interval Exclusion Criteria: 1. kidney transplantation 2. acute inflammatory disease or active cancer
Where this trial is running
Nice, Alpes Maritimes
- CHU de Nice — Nice, Alpes Maritimes, France (Recruiting)
Study contacts
- Principal investigator: Favre Guillaume, PhD — CHU de Nice, Service de Néphrologie
- Study coordinator: Favre Guillaume, PhD
- Email: favre.g@chu-nice.fr
- Phone: 0492038428
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.